Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for rare and difficult-to-treat diseases. The company has a proven track record of bringing therapies to market, with a portfolio that includes treatments for Lambert-Eaton Myasthenic Syndrome (LEMS), Duchenne Muscular Dystrophy (DMD), and epilepsy. In May 2026, Catalyst Pharmaceuticals entered into a definitive agreement to be acquired by Angelini Pharma for approximately $4.1 billion in cash. This acquisition is intended to establish Angelini's presence in the North American market while complementing its existing European rare disease portfolio.